Richardson P, Beksaç M, Oriol A, Lindsay J, Schjesvold F, Galli M, Yağcı M, Larocca A, Weisel K, Yu X, Donahue C, Acosta J, Peluso T, Dimopoulos M (2025)
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
Eur J Haematol (in press)
DOI 10.1111/ejh.14365, PubMed 39777934

Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P et al. (2024)
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
N Engl J Med (in press)
DOI 10.1056/NEJMoa2409029, PubMed 39652675

Rosenberg T, Möller S, Abildgaard N, Nørgaard JN, Lysén A, Tsykonova G, Joao C, Vangsted A, Schjesvold F, Nielsen LK (2024)
Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study
Eur J Haematol (in press)
DOI 10.1111/ejh.14358, PubMed 39638553